Insider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells 20,315 Shares of Stock

Aileron Therapeutics, Inc. (NASDAQ:ALRN) major shareholder Of Texas/Texas Am I. University sold 20,315 shares of Aileron Therapeutics stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $4.21, for a total value of $85,526.15. Following the completion of the transaction, the insider now directly owns 1,779,306 shares in the company, valued at $7,490,878.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Aileron Therapeutics Stock Performance

Shares of NASDAQ:ALRN traded down $0.39 during midday trading on Wednesday, reaching $4.16. The company’s stock had a trading volume of 483,852 shares, compared to its average volume of 74,160. Aileron Therapeutics, Inc. has a fifty-two week low of $1.01 and a fifty-two week high of $7.42. The firm has a 50 day moving average price of $5.43 and a two-hundred day moving average price of $3.82. The firm has a market capitalization of $70.60 million, a price-to-earnings ratio of -1.23 and a beta of 2.22.

Aileron Therapeutics (NASDAQ:ALRN) last released its earnings results on Monday, April 15th. The company reported ($1.54) earnings per share (EPS) for the quarter. As a group, research analysts anticipate that Aileron Therapeutics, Inc. will post -0.62 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aileron Therapeutics stock. Sigma Planning Corp bought a new position in shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 16,580 shares of the company’s stock, valued at approximately $51,000. Sigma Planning Corp owned approximately 0.34% of Aileron Therapeutics at the end of the most recent reporting period. 90.89% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH upped their price objective on shares of Aileron Therapeutics from $9.00 to $19.00 and gave the company a “buy” rating in a research note on Thursday, April 18th.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.